Azora Therapeutics: annual meeting adjourned again to Oct. 26 pending Nasdaq approval
The filing, which names Adial Pharmaceuticals, Inc. as the filer, says the company adjourned its 2026 Annual Meeting of Stockholders for a second time on October 15, 2026, for votes on Proposals 3, 4, 5 and 6. The company had not yet received Nasdaq's approval of its Initial Listing Application, which it submitted in connection with those proposals. Shareholders who already voted on those proposals need not act unless they want to change their vote.
Key points
- Proposals 3, 4, 5 and 6 remain open; the meeting will reconvene on October 26, 2026, at 8:30 a.m. Eastern Time.
- Proposals 1, 2, 7, 8, 9, 10, 11 and 12 were voted on at the September 17, 2026 session.
- Nasdaq approval of the Initial Listing Application was still pending as of October 15, 2026.
- The record date remains August 17, 2026, and no changes were made to the proposals.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.